Ashling Wahner

Associate Editor, OncLive

Ashling Wahner joined MJH Life Sciences in 2022. She produces OncLive's podcast, OncLive On Air, and helps ensure timely publication of news content and announcements from the FDA approval pipeline. She also attends conferences live and virtually to conduct video interviews and produce written coverage. Email: awahner@mjhlifesciences.com

Articles

Dr Goulart on the Efficacy of Frontline Blinatumomab Plus Ponatinib in Ph+ B-ALL

December 7th 2025

Hannah Goulart, MD, discusses the use of first-line blinatumomab plus ponatinib in Philadelphia chromosome–positive B-cell acute lymphoblastic leukemia.

Dr Jen on the Efficacy of an All-Oral, Revumenib-Containing Regimen in AML

December 7th 2025

Wei Ying Jen, MA, BM BCh, M Med, MRCP, FRCPath, discusses the efficacy of revumenib plus decitabine, cedazuridine, and venetoclax in newly diagnosed AML.

Dr George on Early Insights and Future Directions for Water Vapor Thermal Therapy in Prostate Cancer

December 5th 2025

Arvin K. George, MD, discusses the mechanism of water vapor thermal therapy and the implications of VAPOR 2 findings in prostate cancer management.

Dr Lyon on Logistical and Clinical Challenges Associated With Intravesical Therapy for NMIBC

December 5th 2025

Timothy D. Lyon, MD, discuss logistical and clinical challenges faced by patients with non–muscle-invasive bladder cancer who undergo intravesical therapy.

Dr Jhaveri on the FDA Approval of Imlunestrant for ESR1+ Breast Cancer

December 5th 2025

Komal Jhaveri, MD, FACP, discusses the clinical implications of the FDA approval of imlunestrant for pretreated, ESR1-mutated advanced breast cancer.

Inside the Most Anticipated CLL Abstracts: What to Expect From ASH 2025

December 5th 2025

Ahead of the 2025 ASH Annual Meeting, OncLive spoke with experts in CLL care to preview the most anticipated meeting abstracts.

VISION Data Show Promise of Tepotinib in Treatment-Naive NSCLC Harboring MET Exon 14 Skipping Mutations: With Catherine Shu, MD

December 5th 2025

Dr Shu discusses updated data from the VISION trial of tepotinib in patients with non–small cell lung cancer harboring MET exon 14 skipping mutations.

Dr Smith on the Role of Radioligand Therapy in Prostate Cancer

December 4th 2025

Matthew R. Smith, MD, PhD, discusses how radioligand therapies are altering the prostate cancer treatment paradigm.

Dr Gonzalez-Martin on the Efficacy of TUB-040 in Ovarian Cancer

December 3rd 2025

Antonio Gonzalez-Martin, MD, discusses the key efficacy findings from the NAPISTAR1-01 trial of TUB-040 in ovarian cancer.

Dr Bellmunt on Future Directions With ctDNA-Guided Immunotherapy in Urothelial Cancer

December 3rd 2025

Joaquim Bellmunt, MD, PhD, discusses future research directions with ctDNA-guided immunotherapy in urothelial cancer.

PIPAC Reshapes Peritoneal Cancer Surgery Workflows and Outcomes: With Gregory J. Tiesi, MD, FACS, FSSO; Anthony Scholer, MD, FACS, FSSO; Benjamin Jon Golas, MD, FACS; and Eric Pletcher, MD

December 3rd 2025

Drs Tiesi, Scholer, Golas, and Pletcher discussed the use of PIPAC, a minimally invasive regional cancer therapy, in patients with peritoneal cancers.

Maintenance Fuzuloparib Displays PFS Benefit in Newly Diagnosed, Advanced Ovarian Cancer

December 3rd 2025

Fuzuloparib extended PFS vs placebo regardless of the addition of apatinib in newly diagnosed advanced ovarian cancer.

Lower-Intensity Regimens and CAR T-Cell Advances Drive Progress in AML and ALL at ASH 2025

December 3rd 2025

Hematology experts share the AML and ALL abstracts they’re most looking forward to seeing at the 2025 ASH Annual Meeting.

ctDNA Assays Are Poised to Reshape Lymphoma Treatment Strategies: With Sarah Rutherford, MD

December 3rd 2025

Dr Rutherford discusses the use of ctDNA testing for guiding lymphoma management and trials that seek to determine the best use of this type of assay.

IGV-001 Prolongs OS vs Placebo in Newly Diagnosed Glioblastoma

December 2nd 2025

IGV-001 produced an OS benefit vs placebo in newly diagnosed glioblastoma.

sNDA for Aminolevulinic Acid Gel Plus PDT in sBCC Is Submitted to the FDA

December 2nd 2025

Biofrontera has submitted a sNDA to the FDA seeking the approval of aminolevulinic acid gel plus PDT in sBCC.

Revisit Every OncLive On Air Episode From November 2025

December 2nd 2025

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2025.

Personalized Treatment Considerations Guide First-Line Chemo Use in Pancreatic Cancer: With Shubham Pant, MD, MBBS

December 2nd 2025

Dr Pant discusses factors that drive frontline chemotherapy selection for metastatic pancreatic cancer and the role of NALIRIFOX in this treatment setting.

Subcutaneous Pembrolizumab Approved in EU for All Adult Indications

December 1st 2025

Pembrolizumab obtained approval from the European Commission for subcutaneous administration for all adult indications.

CLN-049 Nets FDA Fast Track Designation in Relapsed/Refractory AML

December 1st 2025

The FDA granted fast track designation to CLN-049 for relapsed/refractory acute myeloid leukemia.